Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

Department of Pathology and Laboratory Medicine
Human vaccines & immunotherapeutics 11/2012; 8(11). DOI: 10.4161/hv.22447
Source: PubMed

ABSTRACT There is no licensed vaccine or cure for human cytomegalovirus (CMV), a ubiquitous β-herpesvirus infecting 60-95% of adults worldwide. Infection can cause congenital abnormalities, result in severe disease in immunocompromised patients, and is a major impediment during successful organ transplantation. In addition, it has been associated with numerous inflammatory diseases and cancers, as well as being implicated in the development of essential hypertension, a major risk factor for heart disease. To date, limited data regarding the identification of immunogenic viral targets has frustrated CMV vaccine development. Based upon promising clinical data suggesting an important role for T cells in protecting against disease in the transplantation setting, we designed a novel panel of highly-optimized synthetic vaccines encoding major CMV proteins and evaluated their immune potential in murine studies. Vaccination induced robust CD8+ and CD4+ T cells of great epitopic breadth as extensively analyzed using a novel modified T cell assay described herein. Together with improved levels of CMV-specific T cells as driven by a vaccine, further immune evaluation of each target is warranted. The present model provides an important tool for guiding future immunization strategies against CMV.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Congenital infection of human cytomegalovirus (CMV) is the leading cause of childhood hearing loss and mental retardation. Unfortunately, a preventive vaccine remains elusive. Two strategies have been employed to develop CMV vaccines, including (1) attenuating CMV to generate modified virus vaccines (MVVs) or (2) isolating subunit viral antigen(s) to create individual antigen vaccines (IAVs). The most studied candidate in each category is live attenuated Towne virus and recombinant gB/MF59 vaccine, respectively. Although both were moderately efficacious, neither could induce the durable, robust humoral and cellular immunity commonly seen in CMV seropositive subjects. In addition, both vaccines failed to generate neutralizing antibodies against viral infection of endothelial, epithelial cells and leukocytes. This review discusses the virological basis of CMV tropism and its implications for vaccine design. We also highlight some recent key discoveries that may lead to the development of an effective CMV vaccine.
    Current opinion in virology. 03/2014; 6C:13-23.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Congenital human cytomegalovirus (HCMV) infection can lead to long-term neurodevelopmental sequelae, including mental retardation and sensorineural hearing loss. Unfortunately, CMVs are highly adapted to their specific species, precluding the evaluation of HCMV vaccines in animal models prior to clinical trials. Several species-specific CMVs have been characterized and developed in models of pathogenesis and vaccine-mediated protection against disease. These include the murine CMV (MCMV), the porcine CMV (PCMV), the rhesus macaque CMV (RhCMV), the rat CMV (RCMV), and the guinea pig CMV (GPCMV). Because of the propensity of the GPCMV to cross the placenta, infecting the fetus in utero, it has emerged as a model of particular interest in studying vaccine-mediated protection of the fetus. In this paper, a review of these various models, with particular emphasis on the value of the model in the testing and evaluation of vaccines against congenital CMV, is provided. Recent exciting developments and advances in these various models are summarized, and recommendations offered for high-priority areas for future study.
    Future Virology 12/2013; 8(12):1161-1182. · 1.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A vaccine candidate that elicits humoral and cellular responses to multiple sporozoite and liver-stage antigens may be able to confer protection against Plasmodium falciparum (Pf) malaria, however, a technology for formulating and delivering such a vaccine has remained elusive. Here, we report the preclinical assessment of an optimized DNA vaccine approach that targets four Pf antigens: circumsporozoite protein (CSP), liver stage antigen 1 (LSA1), thrombospondin-related-anonymous-protein (TRAP), and cell-traversal protein for ookinetes and sporozoites (CelTOS). Synthetic DNA sequences were designed for each antigen with modifications to improve expression, and were delivered using in vivo electroporation (EP). Immunogenicity was evaluated in mice and non-human primates (NHPs) and assessed by ELISA, IFNγ ELISpot, and flow cytometry. In mice, DNA+EP delivery induced antigen-specific IFNγ production as measured by ELISpot and IgG seroconversion against all antigens. Sustained production of IFNγ, IL-2 and TNFα was elicited in both the CD4(+) and CD8(+) T cell compartments. Furthermore, hepatic CD8(+) lymphocytes produced LSA1-specific IFNγ. The immune responses conferred in mice by this approach translated to the NHP model showing cellular responses by ELISPOT assay and intracellular cytokine staining. Notably, antigen-specific CD8(+) Granzyme B(+) T cells were observed in NHPs. Collectively, the data demonstrate that delivery of gene sequences by DNA/EP encoding malaria parasite antigens is immunogenic in animal models and can harness both the humoral and cellular arms of the immune system.
    Infection and immunity 07/2013; · 4.16 Impact Factor


Available from
Oct 30, 2014